These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 11204657)
1. Safety of oxaliplatin in the treatment of colorectal cancer. Haller DG Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):15-20. PubMed ID: 11204657 [TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. Chen ML; Fang CH; Liang LS; Dai LH; Wang XK Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of oxaliplatin in the treatment of colorectal cancer. Rothenberg ML Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):9-14. PubMed ID: 11204666 [TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin in colorectal cancer: current studies. Goldberg R Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):42-7. PubMed ID: 11204663 [TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947 [TBL] [Abstract][Full Text] [Related]
6. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567 [TBL] [Abstract][Full Text] [Related]
7. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Twelves C Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer. Mitchell EP Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):30-2. PubMed ID: 11204660 [TBL] [Abstract][Full Text] [Related]
9. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
10. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808 [TBL] [Abstract][Full Text] [Related]
11. Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. LaRocca RV; Glisson SD; Hargis JB; Kosfeld RE; Leaton KE; Hicks RM; Amin-Zimmerman F South Med J; 2004 Sep; 97(9):831-5. PubMed ID: 15455965 [TBL] [Abstract][Full Text] [Related]
12. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661 [TBL] [Abstract][Full Text] [Related]
13. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933 [TBL] [Abstract][Full Text] [Related]
15. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736 [TBL] [Abstract][Full Text] [Related]
17. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840 [TBL] [Abstract][Full Text] [Related]